MBIO
Mustang Bio Inc
$
1.230
Line
|
Candle
1D
5D
1M
3M
6M
YTD
1Y
5Y
High
1.245
Open
1.240
VWAP
1.24
Vol
20.99K
Mkt Cap
9.12M
Low
1.230
Amount
25.99K
EV/EBITDA(TTM)
--
Total Shares
31.26M
EV
-9.86M
EV/OCF(TTM)
--
P/S(TTM)
--
Mustang Bio, Inc. is a clinical-stage biopharmaceutical company focused on translating medical breakthroughs into potential cures for cancers and autoimmune diseases. The Company has partnered with medical institutions to advance the development of chimeric antigen receptor modified T cell (CAR T) therapies. Its pipeline is focused in two core areas: CAR T therapies for autoimmune diseases and hematologic malignancies and CAR T therapies for solid tumors. It is developing a CAR T therapy for hematologic malignancies and autoimmune diseases in partnership with Fred Hutchinson Cancer Center targeting CD20 and for solid tumors in partnership with City of Hope National Medical Center targeting IL13Ra2. It has also partnered with Nationwide Children’s Hospital for a herpes simplex virus type 1 oncolytic virus to enhance the activity of MB-101 for the treatment of patients with high-grade malignant brain tumors.
Show More
Valuation Metrics
The current forward P/E ratio for Mustang Bio Inc (MBIO.O) is -0.07, compared to its 5-year average forward P/E of -2.07. For a more detailed relative valuation and DCF analysis to assess Mustang Bio Inc 's fair value, click here.
Forward PE
The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
N/A
5Y Average PE
-2.07
Current PE
-0.07
Overvalued PE
0.70
Undervalued PE
-4.83
Forward EV/EBITDA
The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
N/A
5Y Average EV/EBITDA
-0.33
Current EV/EBITDA
0.00
Overvalued EV/EBITDA
0.64
Undervalued EV/EBITDA
-1.29
Forward PS
The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
N/A
5Y Average PS
0.01
Current PS
1.25
Overvalued PS
0.14
Undervalued PS
-0.12
Financials
Annual
Quarterly
FY2025Q3
N/A
Total Revenue
FY2025Q3
YoY :
-57.17%
-624.00K
Operating Profit
FY2025Q3
YoY :
-100.00%
N/A
Net Income after Tax
FY2025Q3
YoY :
-96.34%
-0.07
EPS - Diluted
FY2025Q3
YoY :
-100.00%
N/A
Free Cash Flow
Trading Trends
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
0.0
USD
0
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
0-3
Months
0.0
Volume
0
3-6
Months
0.0
Volume
0
6-9
Months
0.0
Volume
0
0-12
Months
0.0
Volume
0
Bought
0-3
0
0.0
Volume
Months
3-6
0
0.0
Volume
Months
6-9
0
0.0
Volume
Months
0-12
0
0.0
Volume
Months
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
0.0
USD
0
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
0.0
USD
0
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
MBIO News & Events
Events Timeline
2025-07-07 (ET)
2025-07-07
08:32:00
Mustang Bio granted orphan drug designation by FDA for MB-101
2025-07-01 (ET)
2025-07-01
12:21:16
Mustang Bio treatment of malignant glioma granted orphan designation
2025-03-05 (ET)
2025-03-05
16:38:16
Mustang Bio regains compliance with Nasdaq requirement
Sign Up For More Events
Sign Up For More Events
News
5.0
08-28Yahoo FinanceCascade Prodrug Inc. Names Industry Experts Manuel (Manny) Litchman and Andres Gutierrez to Its Board of Directors
2.0
07-09BenzingaCalidi Biotherapeutics Stock Jumps 39% After Hours — What's Going On
2.0
07-08TipRanks3 Penny Stocks to Watch Now, 7/8/25
Sign Up For More News
People Also Watch
UGRO
urban-gro Inc
0.294
USD
-4.24%
SEED
Origin Agritech Ltd
1.391
USD
-1.42%
DLPN
Dolphin Entertainment Inc
1.600
USD
-4.19%
LCFY
Locafy Ltd
3.950
USD
0.00%
PMCB
PharmaCyte Biotech Inc
0.816
USD
-4.11%
NTRP
NextTrip Inc
4.440
USD
0.00%
MI
Nft Ltd
3.360
USD
-10.18%
BMRA
Biomerica Inc
2.500
USD
-0.79%
KPRX
Kiora Pharmaceuticals Inc
2.250
USD
-2.39%
FAQ
What is Mustang Bio Inc (MBIO) stock price today?
The current price of MBIO is 1.23 USD — it has decreased -1.6 % in the last trading day.
What is Mustang Bio Inc (MBIO)'s business?
What is the price predicton of MBIO Stock?
What is Mustang Bio Inc (MBIO)'s revenue for the last quarter?
What is Mustang Bio Inc (MBIO)'s earnings per share (EPS) for the last quarter?
What changes have occurred in the market's expectations for Mustang Bio Inc (MBIO)'s fundamentals?
How many employees does Mustang Bio Inc (MBIO). have?